Figure 2.
Kaplan-Meier PFS and OS estimates. Survival analysis included 40 patients with evaluable disease completing at least 1 dose of ibrutinib. Median PFS was 14.0 months (95% CI, 7.4-16.3 months). Median OS was not reached. NA, not achieved.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.